 Christopher Ford
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 23 | 2026 | 289 | 6.390 |
Why?
| | Receptors, Dopamine D2 | 14 | 2026 | 93 | 5.210 |
Why?
| | Corpus Striatum | 13 | 2025 | 179 | 4.560 |
Why?
| | Synaptic Transmission | 14 | 2026 | 290 | 2.960 |
Why?
| | Cholinergic Neurons | 4 | 2019 | 18 | 2.150 |
Why?
| | Neurons | 22 | 2026 | 1642 | 2.080 |
Why?
| | Nucleus Accumbens | 7 | 2026 | 135 | 2.070 |
Why?
| | Inhibitory Postsynaptic Potentials | 9 | 2016 | 48 | 1.950 |
Why?
| | Dopaminergic Neurons | 8 | 2025 | 67 | 1.550 |
Why?
| | Synapses | 8 | 2026 | 439 | 1.490 |
Why?
| | Ventral Tegmental Area | 9 | 2025 | 60 | 1.430 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 3 | 2026 | 228 | 1.420 |
Why?
| | Substantia Nigra | 7 | 2023 | 63 | 1.370 |
Why?
| | Receptor, Muscarinic M4 | 2 | 2024 | 3 | 1.370 |
Why?
| | Locus Coeruleus | 4 | 2025 | 25 | 1.220 |
Why?
| | Signal Transduction | 10 | 2026 | 5233 | 1.180 |
Why?
| | Interneurons | 6 | 2021 | 128 | 1.160 |
Why?
| | Glutamic Acid | 5 | 2025 | 251 | 1.120 |
Why?
| | Mice | 35 | 2026 | 18365 | 0.910 |
Why?
| | Ganglia, Sympathetic | 4 | 2008 | 14 | 0.890 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2024 | 14 | 0.870 |
Why?
| | Norepinephrine | 5 | 2026 | 196 | 0.870 |
Why?
| | Levodopa | 1 | 2024 | 41 | 0.860 |
Why?
| | Dynorphins | 2 | 2022 | 8 | 0.820 |
Why?
| | Animals | 45 | 2026 | 38109 | 0.810 |
Why?
| | Parkinsonian Disorders | 2 | 2021 | 43 | 0.780 |
Why?
| | Receptors, Dopamine D1 | 2 | 2021 | 35 | 0.780 |
Why?
| | Neostriatum | 2 | 2021 | 37 | 0.760 |
Why?
| | Acetylcholine | 5 | 2024 | 206 | 0.760 |
Why?
| | Cholinergic Agents | 2 | 2019 | 18 | 0.750 |
Why?
| | Learning | 1 | 2026 | 452 | 0.710 |
Why?
| | Neurotransmitter Agents | 5 | 2023 | 82 | 0.710 |
Why?
| | Neural Inhibition | 5 | 2009 | 178 | 0.700 |
Why?
| | Dendrites | 4 | 2025 | 106 | 0.700 |
Why?
| | Thalamus | 2 | 2021 | 126 | 0.690 |
Why?
| | Parasympathetic Nervous System | 1 | 2021 | 26 | 0.670 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.660 |
Why?
| | Parkinson Disease | 2 | 2024 | 600 | 0.640 |
Why?
| | Cocaine-Related Disorders | 1 | 2021 | 132 | 0.620 |
Why?
| | Cocaine | 2 | 2021 | 161 | 0.620 |
Why?
| | Action Potentials | 5 | 2019 | 507 | 0.610 |
Why?
| | Optogenetics | 5 | 2024 | 109 | 0.600 |
Why?
| | Mesencephalon | 5 | 2023 | 65 | 0.590 |
Why?
| | Calcium Channels | 4 | 2019 | 154 | 0.590 |
Why?
| | Mice, Inbred C57BL | 15 | 2025 | 5997 | 0.550 |
Why?
| | Patch-Clamp Techniques | 11 | 2012 | 289 | 0.550 |
Why?
| | Receptors, Opioid | 1 | 2016 | 23 | 0.500 |
Why?
| | Cerebral Cortex | 1 | 2019 | 465 | 0.470 |
Why?
| | Receptor, Serotonin, 5-HT1A | 1 | 2015 | 36 | 0.470 |
Why?
| | Neuronal Plasticity | 4 | 2024 | 309 | 0.460 |
Why?
| | Serotonergic Neurons | 1 | 2015 | 29 | 0.460 |
Why?
| | Nerve Growth Factors | 2 | 2008 | 78 | 0.460 |
Why?
| | Raphe Nuclei | 1 | 2015 | 111 | 0.440 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2008 | 212 | 0.430 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2014 | 11 | 0.420 |
Why?
| | Receptors, Nicotinic | 1 | 2016 | 323 | 0.410 |
Why?
| | Potassium Channels | 3 | 2010 | 145 | 0.410 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 2 | 2004 | 32 | 0.410 |
Why?
| | Axons | 3 | 2023 | 201 | 0.400 |
Why?
| | Electric Stimulation | 6 | 2012 | 276 | 0.370 |
Why?
| | Corticotropin-Releasing Hormone | 3 | 2022 | 72 | 0.360 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2025 | 193 | 0.360 |
Why?
| | Synaptic Vesicles | 2 | 2023 | 40 | 0.340 |
Why?
| | Male | 27 | 2025 | 72406 | 0.330 |
Why?
| | Mice, Transgenic | 4 | 2025 | 2185 | 0.320 |
Why?
| | In Vitro Techniques | 7 | 2012 | 1048 | 0.320 |
Why?
| | Mice, Inbred DBA | 5 | 2015 | 187 | 0.300 |
Why?
| | Egtazic Acid | 2 | 2009 | 38 | 0.300 |
Why?
| | Time Factors | 8 | 2014 | 7183 | 0.290 |
Why?
| | Sodium Channels | 2 | 2010 | 63 | 0.290 |
Why?
| | Receptors, AMPA | 2 | 2021 | 147 | 0.290 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 3 | 2016 | 10 | 0.280 |
Why?
| | Sucrose | 2 | 2025 | 115 | 0.270 |
Why?
| | Organ Culture Techniques | 3 | 2014 | 154 | 0.270 |
Why?
| | Electrochemistry | 4 | 2012 | 74 | 0.270 |
Why?
| | Long-Term Potentiation | 2 | 2026 | 200 | 0.260 |
Why?
| | Adrenergic Neurons | 2 | 2018 | 7 | 0.260 |
Why?
| | Receptors, Opioid, kappa | 1 | 2006 | 9 | 0.250 |
Why?
| | Rana catesbeiana | 5 | 2008 | 12 | 0.240 |
Why?
| | Narcotics | 1 | 2006 | 58 | 0.230 |
Why?
| | Limbic System | 1 | 2006 | 55 | 0.230 |
Why?
| | Vesicular Glutamate Transport Proteins | 1 | 2025 | 2 | 0.230 |
Why?
| | Septal Nuclei | 1 | 2025 | 23 | 0.220 |
Why?
| | GABA Antagonists | 3 | 2010 | 34 | 0.220 |
Why?
| | Serotonin | 3 | 2015 | 294 | 0.220 |
Why?
| | Exploratory Behavior | 1 | 2025 | 86 | 0.220 |
Why?
| | GABAergic Neurons | 1 | 2025 | 35 | 0.220 |
Why?
| | Prefrontal Cortex | 1 | 2008 | 328 | 0.220 |
Why?
| | Arousal | 1 | 2025 | 157 | 0.210 |
Why?
| | Neural Pathways | 3 | 2012 | 311 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2032 | 0.210 |
Why?
| | Female | 19 | 2025 | 78376 | 0.200 |
Why?
| | Protein Biosynthesis | 2 | 2024 | 458 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 4 | 2025 | 2540 | 0.190 |
Why?
| | Reward | 1 | 2025 | 247 | 0.190 |
Why?
| | Calcium | 5 | 2012 | 1184 | 0.190 |
Why?
| | HEK293 Cells | 3 | 2024 | 744 | 0.190 |
Why?
| | Membrane Potentials | 4 | 2011 | 280 | 0.190 |
Why?
| | Movement Disorders | 1 | 2022 | 70 | 0.180 |
Why?
| | Rats | 5 | 2025 | 5614 | 0.180 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 147 | 0.180 |
Why?
| | Basal Ganglia | 1 | 2022 | 57 | 0.180 |
Why?
| | Biophysics | 3 | 2011 | 74 | 0.170 |
Why?
| | Heroin | 1 | 2021 | 29 | 0.170 |
Why?
| | Carrier Proteins | 1 | 2024 | 737 | 0.160 |
Why?
| | Extinction, Psychological | 1 | 2021 | 92 | 0.160 |
Why?
| | Analysis of Variance | 3 | 2012 | 1311 | 0.160 |
Why?
| | Phosphinic Acids | 2 | 2010 | 8 | 0.160 |
Why?
| | Behavior, Animal | 2 | 2021 | 520 | 0.160 |
Why?
| | Propanolamines | 2 | 2010 | 40 | 0.150 |
Why?
| | Adaptor Protein Complex 3 | 1 | 2019 | 3 | 0.150 |
Why?
| | Exocytosis | 1 | 2019 | 84 | 0.140 |
Why?
| | Enzyme Inhibitors | 4 | 2008 | 826 | 0.140 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2018 | 37 | 0.140 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2018 | 10 | 0.140 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2018 | 17 | 0.140 |
Why?
| | Botulinum Toxins | 1 | 2019 | 46 | 0.140 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2018 | 15 | 0.140 |
Why?
| | Single-Domain Antibodies | 1 | 2018 | 15 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 701 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2024 | 1167 | 0.130 |
Why?
| | Oxidopamine | 1 | 2017 | 14 | 0.130 |
Why?
| | Chelating Agents | 2 | 2009 | 73 | 0.130 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2016 | 11 | 0.130 |
Why?
| | Ambenonium Chloride | 1 | 2016 | 1 | 0.120 |
Why?
| | Subthalamic Nucleus | 1 | 2017 | 83 | 0.120 |
Why?
| | Cholinesterase Inhibitors | 1 | 2016 | 46 | 0.120 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1143 | 0.120 |
Why?
| | Neurotensin | 1 | 2015 | 13 | 0.120 |
Why?
| | Vesicular Inhibitory Amino Acid Transport Proteins | 2 | 2025 | 10 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2019 | 4155 | 0.110 |
Why?
| | Drug Interactions | 2 | 2006 | 401 | 0.100 |
Why?
| | Stress, Psychological | 2 | 2015 | 1153 | 0.100 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4569 | 0.100 |
Why?
| | Ion Channel Gating | 2 | 2004 | 92 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2011 | 108 | 0.100 |
Why?
| | Mice, Knockout | 2 | 2018 | 3125 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2018 | 791 | 0.090 |
Why?
| | Guinea Pigs | 1 | 2012 | 159 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2015 | 699 | 0.090 |
Why?
| | Methyl-CpG-Binding Protein 2 | 1 | 2011 | 21 | 0.090 |
Why?
| | Species Specificity | 1 | 2012 | 574 | 0.080 |
Why?
| | Iontophoresis | 1 | 2010 | 11 | 0.080 |
Why?
| | Adenosine Triphosphate | 2 | 2003 | 498 | 0.080 |
Why?
| | Calcineurin | 2 | 2024 | 105 | 0.080 |
Why?
| | Picrotoxin | 1 | 2009 | 12 | 0.080 |
Why?
| | Quinpirole | 1 | 2009 | 10 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 86 | 0.080 |
Why?
| | Dizocilpine Maleate | 1 | 2009 | 24 | 0.080 |
Why?
| | Rhodamines | 1 | 2009 | 21 | 0.080 |
Why?
| | Dopamine Agonists | 1 | 2009 | 42 | 0.080 |
Why?
| | Receptors, Dopamine | 2 | 2024 | 19 | 0.070 |
Why?
| | Quinoxalines | 1 | 2009 | 65 | 0.070 |
Why?
| | Calcium Channels, T-Type | 1 | 2010 | 105 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 427 | 0.070 |
Why?
| | Phorbol Esters | 1 | 2008 | 13 | 0.070 |
Why?
| | rap1 GTP-Binding Proteins | 1 | 2008 | 6 | 0.070 |
Why?
| | Receptors, Presynaptic | 1 | 2007 | 9 | 0.070 |
Why?
| | Anxiety | 1 | 2015 | 1110 | 0.070 |
Why?
| | Electric Conductivity | 2 | 2004 | 84 | 0.070 |
Why?
| | Humans | 9 | 2024 | 144957 | 0.070 |
Why?
| | Sulpiride | 2 | 2022 | 5 | 0.060 |
Why?
| | Synaptic Membranes | 1 | 2006 | 16 | 0.060 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2007 | 117 | 0.060 |
Why?
| | Organic Chemicals | 1 | 2008 | 127 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2008 | 292 | 0.060 |
Why?
| | Temperature | 1 | 2009 | 679 | 0.060 |
Why?
| | Bicuculline | 1 | 2006 | 18 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 27 | 0.060 |
Why?
| | Microinjections | 1 | 2006 | 92 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1718 | 0.060 |
Why?
| | Indoles | 1 | 2010 | 501 | 0.060 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2006 | 71 | 0.060 |
Why?
| | Biotin | 1 | 2006 | 32 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2006 | 140 | 0.060 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 1 | 2026 | 69 | 0.060 |
Why?
| | Arcuate Nucleus of Hypothalamus | 1 | 2025 | 12 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2024 | 2609 | 0.060 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2025 | 33 | 0.060 |
Why?
| | Vesicular Glutamate Transport Protein 2 | 1 | 2025 | 15 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 321 | 0.060 |
Why?
| | Visual Cortex | 1 | 2026 | 84 | 0.060 |
Why?
| | Dialysis | 1 | 2004 | 18 | 0.060 |
Why?
| | Luminescent Proteins | 1 | 2026 | 185 | 0.050 |
Why?
| | Avoidance Learning | 1 | 2025 | 65 | 0.050 |
Why?
| | Photometry | 1 | 2024 | 3 | 0.050 |
Why?
| | Naloxone | 1 | 2006 | 132 | 0.050 |
Why?
| | Intracellular Space | 1 | 2004 | 66 | 0.050 |
Why?
| | Amygdala | 1 | 2006 | 198 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2024 | 98 | 0.050 |
Why?
| | NFATC Transcription Factors | 1 | 2024 | 93 | 0.050 |
Why?
| | Reaction Time | 1 | 2006 | 438 | 0.050 |
Why?
| | Vesicular Monoamine Transport Proteins | 1 | 2023 | 9 | 0.050 |
Why?
| | Astrocytes | 1 | 2026 | 224 | 0.050 |
Why?
| | Analgesics | 1 | 2006 | 231 | 0.050 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2003 | 8 | 0.050 |
Why?
| | 1-Phosphatidylinositol 4-Kinase | 1 | 2003 | 3 | 0.050 |
Why?
| | Calcium Channels, N-Type | 1 | 2003 | 12 | 0.050 |
Why?
| | Receptors, LHRH | 1 | 2003 | 14 | 0.050 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2003 | 3 | 0.050 |
Why?
| | Denervation | 1 | 2003 | 27 | 0.050 |
Why?
| | Narcotic Antagonists | 1 | 2006 | 206 | 0.050 |
Why?
| | Muscarinic Agonists | 1 | 2003 | 14 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2003 | 47 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2024 | 2832 | 0.050 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2003 | 15 | 0.050 |
Why?
| | Receptors, GABA-A | 1 | 2024 | 138 | 0.050 |
Why?
| | Heparin | 1 | 2004 | 244 | 0.050 |
Why?
| | Androstadienes | 1 | 2003 | 76 | 0.050 |
Why?
| | Aluminum | 1 | 2003 | 43 | 0.050 |
Why?
| | COS Cells | 1 | 2003 | 181 | 0.050 |
Why?
| | Recurrence | 2 | 2021 | 1135 | 0.050 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2003 | 55 | 0.050 |
Why?
| | Hyperkinesis | 1 | 2022 | 16 | 0.050 |
Why?
| | Histone Deacetylases | 1 | 2024 | 210 | 0.050 |
Why?
| | Type C Phospholipases | 1 | 2002 | 69 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2003 | 118 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 359 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2931 | 0.040 |
Why?
| | Sympathetic Nervous System | 1 | 2002 | 178 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 124 | 0.040 |
Why?
| | Antibodies | 1 | 2003 | 403 | 0.040 |
Why?
| | Hippocampus | 1 | 2026 | 967 | 0.040 |
Why?
| | Dopamine Antagonists | 2 | 2011 | 25 | 0.040 |
Why?
| | Gait | 1 | 2022 | 313 | 0.040 |
Why?
| | Vesicle-Associated Membrane Protein 2 | 1 | 2019 | 14 | 0.040 |
Why?
| | SNARE Proteins | 1 | 2019 | 40 | 0.040 |
Why?
| | Electrophysiology | 2 | 2010 | 218 | 0.040 |
Why?
| | Protein Binding | 2 | 2018 | 2276 | 0.040 |
Why?
| | Cryptochromes | 1 | 2019 | 25 | 0.040 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2018 | 2 | 0.040 |
Why?
| | Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 6 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 1046 | 0.030 |
Why?
| | Gene Expression | 1 | 2003 | 1490 | 0.030 |
Why?
| | Guanosine Triphosphate | 1 | 2018 | 89 | 0.030 |
Why?
| | Arabidopsis Proteins | 1 | 2019 | 76 | 0.030 |
Why?
| | Dimerization | 1 | 2018 | 194 | 0.030 |
Why?
| | Ribosomes | 1 | 2018 | 191 | 0.030 |
Why?
| | Light | 1 | 2019 | 411 | 0.030 |
Why?
| | Protein Kinase C | 2 | 2010 | 252 | 0.030 |
Why?
| | Receptors, Neurotensin | 1 | 2015 | 11 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1371 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2019 | 337 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1331 | 0.030 |
Why?
| | Presynaptic Terminals | 1 | 2015 | 86 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 863 | 0.030 |
Why?
| | Brain | 1 | 2026 | 2941 | 0.020 |
Why?
| | Radioligand Assay | 1 | 2011 | 37 | 0.020 |
Why?
| | Tritium | 1 | 2011 | 68 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1496 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4099 | 0.020 |
Why?
| | Neural Conduction | 1 | 2011 | 92 | 0.020 |
Why?
| | Electrochemical Techniques | 1 | 2011 | 55 | 0.020 |
Why?
| | Cochlear Nucleus | 1 | 2010 | 5 | 0.020 |
Why?
| | Receptors, Dopamine D3 | 1 | 2010 | 5 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 2010 | 57 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2010 | 113 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 224 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3415 | 0.020 |
Why?
| | Receptors, GABA-B | 1 | 2009 | 10 | 0.020 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 28 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2009 | 75 | 0.020 |
Why?
| | Colforsin | 1 | 2007 | 48 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 59 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 185 | 0.020 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2009 | 188 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 2114 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3335 | 0.010 |
Why?
| | Phenanthridines | 1 | 2002 | 7 | 0.010 |
Why?
| | Benzophenanthridines | 1 | 2002 | 10 | 0.010 |
Why?
| | Thapsigargin | 1 | 2002 | 20 | 0.010 |
Why?
| | Estrenes | 1 | 2002 | 17 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 20 | 0.010 |
Why?
| | Culture Techniques | 1 | 2002 | 67 | 0.010 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 29 | 0.010 |
Why?
| | Alkaloids | 1 | 2002 | 28 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2002 | 29 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2002 | 76 | 0.010 |
Why?
| | ras Proteins | 1 | 2002 | 151 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 210 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2009 | 1094 | 0.010 |
Why?
|
|
Ford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|